The Hypoxic Inducible Stress Response as a Target for Cancer Drug Discovery

Seminars in Oncology

Volumn 33, Issue 4, 2006, Pages 486-497

  Welsh, Sarah J ^a   Koh, Mei Yee ^b   Powis, Garth ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 METHOXYESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; CAMPTOTHECIN DERIVATIVE; CHETOMIN; DIETHYLENE IODONIUM; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ECHINOMYCIN; FR 901228; GELDANAMYCIN; GUANYLATE CYCLASE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR 1; KF 58333; MITOGEN ACTIVATED PROTEIN KINASE; NSC 13502; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLEUROTIN; PROTEIN INHIBITOR; PROTEIN P53; PX 12; PX 478; RADICICOL; RAPAMYCIN; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; WORTMANNIN;

ALPHA CHAIN; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL HYPOXIA; CELL LABELING; CONTRAST ENHANCEMENT; ERYTHROPOIESIS; GENE OVEREXPRESSION; HEMANGIOBLASTOMA; HIGH THROUGHPUT SCREENING; HUMAN; INTERNAL RIBOSOME ENTRY SITE; METASTASIS INHIBITION; MICROTUBULE ASSEMBLY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; RNA INTERFERENCE; TARGET CELL DESTRUCTION; THREE DIMENSIONAL IMAGING; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR BIOPSY; UBIQUITINATION; UPREGULATION;

ANTIGENS, NEOPLASM; DRUGS, INVESTIGATIONAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; NERVE TISSUE PROTEINS; RIBONUCLEOPROTEINS, SMALL NUCLEAR; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 33746564193     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.04.011     Document Type: Article

References (158)

1. Brown J.M. Exploiting the hypoxic cancer cell. Mechanisms and therapeutic strategies. Mol Med Today 6 (2000) 157-162
2. Hoeckel M., Schlenger K., Hoeckel S., et al. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59 (2001) 4525-4528
3. Birner P., Gatterbauer B., Oberhuber H., et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas. Its impact on prognosis and on neoangiogenesis. Cancer 92 (2001) 165-171
4. Bos R., Zhong H., Hanrahan C.F., et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93 (2001) 309-314
5. Bos R., van der Groep P., Greijer A.E., et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97 (2003) 1573-1581
6. Moulder J.D., and Rockwell S. Tumor hypoxia. Its impact on cancer therapy. Cancer Metast Rev 5 (1987) 313-341
7. Nordsmark M., Hoyer M., Keller J., et al. The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 35 (1996) 701-708
8. Thomlinson R., and Gray L. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9 (1955) 539-549
9. Brown J.M., and Giaccia A.J. The unique physiology of solid tumors. Opportunities and (problems) for cancer therapy. Cancer Res 58 (1998) 1408-1416
10. Hoeckel M., Schlenger K., Aral B., et al. Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
11. Semenza G.L. HIF-1 and tumor progession. Pathophysiology and therapeutics. Trends Mol Med 8 (2002) S62-S67
12. Wildiers H., Guetens G., de Boeck G., et al. Melphalan availability in hypoxia-inducible factor-1alpha+/+ and factor-1alpha-/- tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport. Int J Cancer 99 (2002) 514-519
13. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1α in tumor progression. Crit Rev Biochem Mol Biol 35 (2000) 71-103
14. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
15. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
16. Ryan H.E., Lo J., and Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17 (1998) 3005-3015
17. Semenza G.L. Hypoxia-inducible factor 1:oxygen homeostasis and disease pathophysiology. Trends Mol Med 7 (2001) 345-350
18. 2, and the 3 PHDs. How animal cells signal hypoxia to the nucleus. Cell 107 (2002) 1-3
19. Kaelin W.G. Proline hydroxylation and gene expression. Ann Rev Biochem 74 (2005) 115-128
20. Welsh S.J., and Powis G. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Target 3 (2003) 391-405
21. Seagroves T.N., Ryan H.E., Lu H., et al. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol 21 (2001) 3436-3444
22. Ravi R., Mookerjee B., Bhujwalla Z.M., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 alpha. Genes Dev 14 (2000) 34-44
23. Kung A.L., Wang S., Klco J.M., et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 8 (2000) 1335-1340
24. Michel G., Minet E., Ernest I., et al. A model for the complex between the hypoxia-inducible factor-1 (HIF-1) and its consensus DNA sequence. J Biomol Struct Dyn 18 (2000) 169-179
25. Talks K.L., Turley H., Gatter K.C., et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157 (2000) 411-421
26. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12 (1998) 149-162
27. Tian H., Hammer R.E., Matsumoto A.M., et al. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12 (1998) 3320-3324
28. Peng J., Zhang L., Drysdale L., et al. The transcription factor EPAS-1/hypoxia-inducible factor-2α plays an important role in vascular remodelling. Proc Natl Acad Sci U S A 97 (2000) 8386-8391
29. Kozak K.R., Abbott B., and Hanksinson O. ARNT-deficient mice and placental differentiation. Dev Biol 191 (1997) 297-305
30. Lang K.J.D., Kappel A., and Goodall G.J. Hypoxia-inducible factor-1α mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 13 (2002) 1792-1801
31. Jeong J.W., Bae M.K., Ahn M.Y., et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111 (2002) 709-720
32. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 95 (1998) 7987-7992
33. Kallio P.J., Wilson W.J., O'Brien S., et al. Regulation of the hypoxia-inducible factor-1α by the ubiquitin-proteasome pathway. J Biol Chem 274 (1999) 6519-6525
34. Salceda S., and Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends upon redox-induced changes. J Biol Chem 272 (1997) 22642-22647
35. Jiang B.H., Rue E., Wang G.L., et al. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271 (1996) 17771-17778
36. Mahon P.C., Hirota K., and Semenza G.L. FIH-1. A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15 (2001) 2675-2686
37. Sang N., Fang J., Srinivas V., et al. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol 22 (2002) 2984-2992
38. Lando D., Peet D.J., Whelan D.A., et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295 (2002) 858-861
39. Carrero P., Okamoto K., Coumailleau P., et al. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1α. Mol Cell Biol 20 (2000) 402-415
40. Ema M., Hirota K., Mimura J., et al. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia. Their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18 (1999) 1905-1914
41. Wang G.L., Jiang B.H., and Semenza G.L. Effect of altered redox states on expression and DNA-binding activity of hypoxia-inducible factor 1. Biochem Biophys Res Commun 212 (1995) 550-556
42. Huang L.E., Arany Z., and Livingston D.M. Activation of hypoxia inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271 (1996) 32253-32259
43. Lando D., Pongratz I., Poellinger L., et al. Redox-regulated recruitmentof the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1α. J Biol Chem 275 (2000) 4618-4627
44. 2 evoked regulation of HIF1α and NF-κB ion perinatal lung epithelium requires glutathione biosynthesis. Am J Physiol 278 (2003) L492-L503
45. Haddad J.J., Olver R.E., and Land S.C. Antioxidant/pro-oxidant equilibrium regulates HIF-1α and NF-κB redox sensitivity. Evidence for inhibition by glutathione oxidation in alveolar epithelial cells. J Biol Chem 275 (2000) 21130-21139
46. Welsh S.J., Bellamy W.T., Briehl M.M., et al. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression. Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62 (2002) 5089-5095
47. Saitoh M., Nishitoh H., Fujii M., et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17 (1998) 2596-2606
48. Hayashi T., Ueno Y., and Okamoto T. Oxidoreductive regulation of nuclear factor kappaB. Involvement of a cellular reducing catalyst thioredoxin. J Biol Chem 268 (1993) 11380-11388
49. Makino Y., Yoshikawa N., Okamoto K., et al. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J Biol Chem 274 (1999) 3182-3188
50. Bloomfield K.L., Osborne S.A., Kennedy D.D., et al. Thioredoxin-mediated redox control of the transcription factor Sp1 and regulation of the thioredoxin gene promoter. Gene 319 (2003) 107-116
51. Ueno M., Masutani H., Jun Arai R., et al. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274 (2000) 35809-35815
52. Kallio P.J., Okamoto K., O'Brian S., et al. Signal transduction in hypoxic cells. inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1 alpha. EMBO J 17 (1998) 6573-6586
53. An W.G., Kanekal M., Simon M.C., et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392 (1998) 405-408
54. Sosnowski R., Mellon P.L., and Lawson M.A. Activation of translation in pituitary gonadotroph cells by gonadotropin-releasing hormone. Mol Endocrinol 14 (2000) 1811-1819
55. Zhou J., Schmid T., Frank R., et al. PI3K/Akt is required or heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem 279 (2004) 13506-13513
56. Zeler E., Levy Y., Kahana C., et al. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J 17 (1998) 5085-5094
57. Agani F., and Semenza G.L. Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity. Mol Pharmacol 54 (1998) 749-754
58. Feldser D., Agani F., Iyer N.V., et al. Reciprocal positive regulation of hypoxia-inducible factor 1 alpha and insulin-like growth factor 2. Cancer Res 59 (1999) 3915-3918
59. Hellwig-Burgel T., Rutkowski K., Metzen E., and wet. Interleukin-1β and tumor necrosis factor-α stimulate DNA binding of hypoxia-inducible factor-1. Blood 94 (1999) 1561-1567
60. Thornton R.D., Lane P., Bordghaei R.C., et al. Interleukin-1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 350 (2000) 307-312
61. Richard D.E., Berra E., and Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells. J Biol Chem 275 (2000) 26765-26771
62. Haddad J.J., and Land S.C. A non-hypoxic ROS-sensitive pathway mediates TNF-α-dependent regulation of HIF-1α. FEBS Lett 505 (2001) 269-274
63. phox-containing NADPH oxidase. Circ Res 89 (2001) 47-54
64. Tacchini L., Dansi P., Matteucci E., et al. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 22 (2001) 1363-1371
65. Stiehl D.P., Jelkmann W., Wenger R.H., et al. Normoxic induction of the hypoxia-inducible factor-1α by insulin and interleukin-1β involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 512 (2002) 157-162
66. Zundel W., Schindler C., Haas-Kogan D., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14 (2000) 391-396
67. Laughner E., Taghavi P., Chiles K., et al. HER2 (neu) signalling increases the rate of hypoxia-inducible factor-1alpha (HIF-1alpha) synthesis. novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21 (2001) 3995-4004
68. Triens C., Giorgetti-Peraldi S., Murdaca J., et al. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signalling pathway. Biol Chem 277 (2002) 27975-27981
69. Isaacs J.S., Jung Y.J., Mimnaugh E.G., et al. Hsp90 regulates a von hippel lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem 277 (2002) 29936-29944
70. Zhong H., De Marco A.M., Laughner E., et al. Over-expression of hypoxia-inducible factor 1 alpha in common human cancers and metastases. Cancer Res 59 (1999) 5830-5835
71. Gradin K., McGuire J., Wenger R.H., et al. Functional interference between hypoxia and dioxin signal transduction pathways. Competition for recruitment of the Arnt transcription factor. Mol Cell Biol 16 (1996) 5221-5231
72. Neufeld G., Kessler O., Vadasz Z., et al. The contribution of proangiogenic factors to the progression of malignant disease. Role of vascular endothelial growth factor and its receptors. Surg Oncol Clin North Am 10 (2001) 339-356
73. Zagzag D., Zhong H., Scalzetti J.M., et al. Expression of hypoxia-inducible factor-1 alpha in brain tumors. Association with angiogenesis, invasion and progression. Cancer 88 (2000) 2606-2618
74. Ohh M., Park C.W., Ivan M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat Cell Biol 2 (2000) 423-427
75. Cockman M.E., Masson N., Mole D.D.R., et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275 (2000) 25733-25741
76. Tanimoto K., Makino Y., Pereira T., et al. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J 19 (2000) 4298-4309
77. Kamura T., Sato S., Iwai K., et al. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 97 (2000) 10430-10435
78. Krieg M., Haas R., Brauch H., et al. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19 (2000) 5435-5443
79. Clifford S.C., Cockma M.D., Smallwood A.C., et al. Contrasting effect on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumorigenesis in von Hippel-Lindau disease. Hum Mol Genet 10 (2001) 1029-1038
80. Vaux E.C., Wood S.M., Cockman M.E., et al. Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor. J Biol Chem 276 (2001) 44323-44330
81. Yu F., White S.B., Zhao Q., et al. Dynamic site-specific interaction of hypoxia-inducible factor-1α with the von Hippel-Lindau tumor suppressor protein. Cancer Res 61 (2001) 4136-4142
82. Maxwell P.H., Wiesener M.S., Chang G.-W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
83. Giatromanolaki A., Koukourakis M.L., Sivridis E., et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic molecular profile of tumors and survival. Br J Cancer 85 (2001) 881-890
84. Birner P., Schindl M., Obermair A., et al. Expression of hypoxia-inducible factor-1 alpha in epithelial ovarian tumors. Its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7 (2001) 1661-1668
85. Aebersold D.M., Burri P., Beer K.T., et al. Expression of hypoxia-inducible factor-1alpha. A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61 (2001) 2911-2916
86. Birner P., Schindl M., Obermair A., et al. Over-expression of hypoxia-inducible factor-1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60 (2000) 4693-4696
87. Volm M., and Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 20 (2000) 1527-1533
88. Giaccia A.J., and Kastan M.B. The complexity of p53 modulation. Emerging patterns from divergent signals. Genes Dev 12 (1998) 2973-2983
89. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
90. Graeber T.G., Peterson J.F., Tsai M., et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 14 (1994) 6264-6277
91. An W.G., Kanekal M., Simon M.C., et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392 (1998) 405-408
92. Wenger R.H., Camenisch G., Desbaillets I., et al. Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. Cancer Res 58 (1998) 5678-5680
93. Pan Y., Oprysko P.R., Asham A.M., et al. p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment. Oncogene 23 (2004) 4975-4983
94. Sanchez-Puig N., Veprintsev D.B., and Fersht A.R. Binding of natively unfolded HIF-1alpha ODD domain to p53. Mol Cell 17 (2005) 11-21
95. An W.G., Kanekal M.C., Simon M.C., et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 392 (1998) 405-408
96. Ravi R., Mookerjee B., Bhujwalla Z.M., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14 (2000) 34-44
97. Ravi R., Mookerjee B., Bhujwalla Z.M., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 14 (2000) 34-44
98. Arany Z., Huang L.E., Eckner R., et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A 93 (1996) 12969-12973
99. Gu W., Shi X.L., and Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature 387 (1997) 819-823
100. Blagosklonny M.V., An W.G., Romanova L.Y., et al. p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273 (1998) 11995-11998
101. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (1999) 5830-5835
102. Su Y.A., Hutter C.M., Trent J.M., et al. Complete sequence analysis of a gene (OS-9) ubiquitously expressed in human tissues and amplified in sarcomas. Mol Carcinog 15 (1996) 270-275
103. Baek J.H., Mahon P.C., Oh J., et al. OS-9 interacts with hypoxia-inducible factor 1α and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1α. Mol Cell 17 (2005) 503-512
104. Detwiller K.Y., Fernando N.T., Segal N.H., et al. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 65 (2005) 5881-5889
105. Vigneron N., Ooms A., Morel S., et al. Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. Cancer Immun 2 (2002) 9-18
106. Gupta M., Mungai P.T., and Goldwasser E. A new transacting factor that modulates hypoxia-induced expression of the erythropoietin gene. Blood 96 (2000) 491-497
107. Shichijo S., Nakao M., Imai Y., et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187 (1998) 277-288
108. Koh YM, Powis G: SART1/HAF, a protein widely over expressed in human cancer, decreases HIF-1α levels and inhibits tumor growth. (unpublished observations)
109. Kawamoto M., Shichijo S., Imai Y., et al. Expression of the SART-1 tumor rejection antigen in breast cancer. Int J Cancer 80 (1999) 64-67
110. Sasatomi T., Yamana H., Shichijo S., et al. Expression of the SART1 tumor-rejection antigens in colorectal cancers. Dis Colon Rectum 43 (2000) 1754-1758
111. Imaizumi T., Kuramoto T., Matsunaga K., et al. Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer 83 (1999) 760-764
112. Matsumoto H., Shichijo S., Kawano K., et al. Expression of the SART-1 antigens in uterine cancers. Jpn J Cancer Res 89 (1998) 1292-1295
113. Cromer A., Carles A., Millon R., et al. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23 (2004) 2484-2498
114. Saunders M., and Dische S. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer 27 (1996) S271-S278
115. Overgaard J., and Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6 (1996) 10-21
116. Naylor M.A., and Thomson P. Recent advances in bioreductive drug targeting. Mini Rev Med Chem 1 (2001) 17-29
117. Sun X., Kanwar J.R., Leung E., et al. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 8 (2001) 638-645
118. Li L., Lin X., Staver M., et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 65 (2005) 7249-7258
119. Agani F., and Semenza G.L. Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity. Mol Pharmacol 54 (1998) 749-754
120. Conrad P.W., Freeman T.L., Beitner-Johnson D., et al. EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. J Biol Chem 274 (1999) 33709-33713
121. Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells. Implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
122. Laughner E., Taghavi P., Chiles K., et al. HER2(neu) signaling increases the rate of hypoxia-inducible factor 1a(HIF-1a) synthesis. Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21 (2001) 3995-4004
123. Sato S., Fujita N., and Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 97 (2000) 10832-10837
124. Xu W., Mimnaugh E., Rossser M.F., et al. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276 (2001) 3702-3708
125. Stancato L.F., Chow Y.H., Hutchison KA, et al. Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J Biol Chem 268 (1993) 21711-21716
126. Brugge J.S., Erikson E., and Erikson R.L. The specific interaction of the Rous sarcoma virus transforming protein pp60src, with two cellular proteins. Cell 25 (1981) 363-372
127. Mimnaugh E.G., Chavany C., and Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271 (1996) 22796-22801
128. Schulte T.W., An W.G., and Neckers L.M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 239 (1997) 55-659
129. Whitesell L., Sutphin P., An W.G., et al. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 14 (1997) 2809-2816
130. Mabjeesh N.J., Post D.E., Willard M.T., et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002 62 (2002) 2478-2482
131. Grem J.L., Morrison G., Guo X.D., et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23 (2005) 1885-1893
132. Nguyen D.M., Desai S., Chen A., et al. Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. Ann Thorac Surg 70 (2000) 1853-1860
133. Kurebayashi J., Otsuki T., Kurosumi M., et al. A radicicol derivative KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn J Can Res 92 (2001) 1342-1351
134. Mabjeesh N.J., Post D.E., Willard M.T., et al. Geldanamycin induces degradation of hypoxia-inducible factor-1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62 (2002) 2478-2482
135. Rapisarda A., Uranchimeg B., Scudiero D.A., et al. Identification of small molecule inhibitors of hypoxia-indiucible factor 1 transcriptional activation pathway. Cancer Res 62 (2002) 4316-4324
136. Tan C., de Noronha R.G., Roecker A.J., et al. Identification of a novel small molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65 (2005) 605-612
137. Rapisarda A., Zalek J., Hollingshead M., et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64 (2004) 6845-6848
138. Lee Y.M., Kim S.H., Kim H.S., et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1 activity. Biochem Biophys Res Commun 300 (2003) 241-246
139. Klauber N., Parangi S., Flynn E., et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 57 (1997) 81-86
140. Avramis I.A., Kwock R., and Avramis V.I. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res 21 (2001) 2281-2286
141. Lakhani N.J., Sarkar M.A., Venitz J., et al. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23 (2003) 165-172
142. Mabjeesh N.J., Escuin D., LaVallee T.M., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
143. Welsh S.J., Williams R.R., Birmingham A., et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol Cancer Ther 2 (2003) 235-243
144. Welsh S.J., Williams R., Kirkpatrick L., et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia inducible factor-1α. Mol Cancer Ther 3 (2004) 233-244
145. Jordan B.F., Runquist M., Raghunand N., et al. Imaging the effects of HIF-1α inhibition by diffusion and dynamic contrast enhanced MRI. Neoplasia 7 (2005) 475-485
146. Jordan B.F., Black K., Robey I.F., et al. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed 18 (2005) 430-439
147. Chun Y.S., Yeo E.J., Choi E., et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 61 (2000) 947-954
148. Yeo E.J., Chun Y.S., Cho Y.S., et al. YC-1. A potential anticancer drug targeting hypoxia-inducible factor1. J Natl Cancer Inst 95 (2003) 516-525
149. Huang L.E., Willmore W.G., Gu J., et al. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J Biol Chem 274 (1999) 9038-9044
150. Wang F., Sekine H., Kikuchi Y., et al. HIF-1alpha-prolyl hydroxylase. Molecular target of nitric oxide in the hypoxic signal transduction pathway. Biochem Biophys Res Commun 295 (2002) 657-662
151. Kong D., Park E.J., Stephen A.G., et al. Echinomycin, a small molecule inhibitor of hypoxia-inducible factor-1 binding activity. Cancer Res 65 (2005) 9047-9055
152. Gradishar W.J., Vogelzang N.J., Kilton L.J., et al. A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center study. Invest New Drugs 13 (1995) 171-174
153. Wadler S., Tenteromano L., Cazenave L., et al. Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemother Pharmacol 34 (1994) 266-269
154. Kung A.L., Zabludoff S.D., France D.S., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004) 33-43
155. Hur E., Chang K.Y., Lee E., et al. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1α. Mol Pharmacol 59 (2001) 1216-1224
156. Escuin D., Kline E.R., and Giannakakou P. Both microtubule-stabilizing and microtubule destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule formation. Cancer Res 65 (2005) 9021-9028
157. Gleadle J.M., Ebert B.L., and Ratcliffe P.J. Diphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia. Implications for the mechanism of oxygen sensing. Eur J Biochem 234 (1995) 92-99
158. Dery M.A., Michaud M.D., and Richard D.E. Hypoxia-inducible factor 1. Regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37 (2005) 535-540